ARQT
Arcutis Biotherapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$27.53-3.37%
Price as of Jul 20, 2026
ARQT financials
Arcutis Biotherapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $376.1M | $196.5M | $59.6M | $3.7M |
| Cost of revenue | $36.7M | $19.1M | $5.0M | $754.0K |
| Gross profit | $339.4M | $177.4M | $54.6M | $2.9M |
| Operating expenses | $351.6M | $305.8M | $295.7M | $304.6M |
| Operating income | -$12.2M | -$128.4M | -$241.1M | -$301.6M |
| Net income | -$16.1M | -$140.0M | -$262.1M | -$311.5M |
| EBITDA | $2.5M | -$109.6M | -$227.4M | -$294.6M |
| Basic EPS | $-0.13 | $-1.16 | $-3.78 | $-5.66 |
| Diluted EPS | $-0.13 | $-1.16 | $-3.78 | $-5.66 |
| Balance sheet | ||||
| Cash & equivalents | $42.9M | $71.3M | $88.4M | $53.6M |
| Total assets | $433.0M | $348.9M | $341.4M | $449.3M |
| Total liabilities | $243.5M | $191.3M | $252.7M | $239.7M |
| Stockholders’ equity | $189.5M | $157.5M | $88.7M | $209.6M |
| Total debt | $6.3M | $110.6M | $205.9M | $202.5M |
| Net debt | -$36.6M | $39.3M | $117.5M | $148.9M |
| Cash flow | ||||
| Operating cash flow | -$5.6M | -$112.2M | -$247.1M | -$257.7M |
| Capital expenditure | -$686.0K | -$143.0K | -$428.0K | -$23.3M |
| Free cash flow | -$6.3M | -$112.3M | -$247.5M | -$281.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |